SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Rosén Mikael)
 

Sökning: WFRF:(Rosén Mikael) > Effects of adjuvant...

Effects of adjuvant tamoxifen therapy on cardiac disease: results from a randomized trial with long-term follow-up

Rosell, Johan (författare)
Östergötlands Läns Landsting,Linköpings universitet,Onkologi,Hälsouniversitetet,Regionalt cancercentrum
Nordenskjöld, Bo (författare)
Östergötlands Läns Landsting,Linköpings universitet,Onkologi,Hälsouniversitetet,Onkologiska kliniken US
Bengtsson, Nils-Olof (författare)
Umeå universitet,Onkologi,Umeå University Hospital, Sweden
visa fler...
Fornander, Tommy (författare)
Karolinska Institutet,Karolinska University Hospital, Sweden
Hatschek, Thomas (författare)
Karolinska Institutet,Karolinska University Hospital, Sweden
Lindman, Henrik (författare)
Uppsala universitet,Enheten för onkologi,University of Uppsala Hospital, Sweden
Malmström, Per (författare)
Lund University,Lunds universitet,Bröstcancer-genetik,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Breastcancer-genetics,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine,Skåne University Hospital, Sweden
Wallgren, Arne (författare)
Sahlgrens University Hospital, Sweden
Stål, Olle (författare)
Östergötlands Läns Landsting,Linköpings universitet,Onkologi,Hälsouniversitetet,Onkologiska kliniken US
Carstensen, John (författare)
Linköpings universitet,Hälsa och samhälle,Hälsouniversitetet
visa färre...
 (creator_code:org_t)
2013-03-02
2013
Engelska.
Ingår i: Breast Cancer Research and Treatment. - New York : SPRINGER, 233 SPRING ST, NEW YORK, NY 10013 USA. - 0167-6806 .- 1573-7217. ; 138:2, s. 467-473
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • Tamoxifen is associated with a reduced risk of coronary heart disease (CHD). However, there are few reports on long-term effects. Using data from a large Swedish randomized trial of 5 and 2 years of adjuvant tamoxifen in women with early breast cancer, we here present results on morbidity and mortality from cardiac diseases during treatment and long-term after treatment. A total of 4,150 patients were breast cancer recurrence-free after 2 years. Data from the Swedish National Hospital Discharge Registry combined with information from the Swedish Cause of Death Registry were used to define events of disease. Hazard ratios were estimated using Cox regression. Patients assigned to 5 years in comparison with 2 years of postoperative tamoxifen experienced a reduced incidence of CHD [hazard ratio (HR), 0.83; 95 % CI 0.70-1.00], especially apparent during the active treatment period (HR 0.65; 95 % CI 0.43-1.00). The mortality from CHD was significantly reduced (HR 0.72; 95 % CI 0.53-0.97). During the active treatment, the morbidity of other heart diseases was also significantly reduced (HR 0.40; 95 % CI 0.25-0.64) but not after treatment stopped (HR 1.06; 95 % CI 0.87-1.30). Similar results were seen for both heart failure and atrial fibrillation/flutter. As compared to 2 years of therapy, 5 years of postoperative tamoxifen therapy prevents CHD as well as other heart diseases. The risk reduction is most apparent during the active treatment period, and later tends to diminish.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Cancer and Oncology (hsv//eng)

Nyckelord

Breast cancer
Tamoxifen
Adjuvant treatment
Adverse events
Heart failure
Coronary heart disease
SOCIAL SCIENCES
SAMHÄLLSVETENSKAP
Breast cancer
Tamoxifen
Adjuvant treatment
Adverse events
Heart
failure
Coronary heart disease

Publikations- och innehållstyp

ref (ämneskategori)
art (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy